Gilead Sciences Stock Forum

Deep-pocketed investors have taken a bullish approach towards $Gilead Sciences(GILD.US)$, Benzinga reported, cited nine extraordinary options activities linked to the stock. About 77% of the trades were leaning bullish and 22% bearish, according to the report.
Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...

$SPDR S&P Biotech ETF(XBI.US)$$iShares Biotechnology ETF(IBB.US)$
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US)$ 's $4.3 b...

$SPDR S&P Biotech ETF(XBI.US)$
$Merck & Co(MRK.US)$ x $Immunovant(IMVT.US)$
$Eli Lilly and Co(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$Gilead Sciences(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$Bristol-Myers Squibb(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US)$ x $Merus(MRUS.US)$ (partner n...

On March 29, $Gilead Sciences(GILD.US)$ and $Xilio Therapeutics(XLO.US)$ ' announced that they have reached an exclusive license agreement totaling more than 600 million US dollars.
Here's a look at some technical analysis: